
Conference Coverage
Latest Content

VPM1002 Fails to Show Noninferiority to BCG in Tuberculosis Prevention Trial

Two More Food Recalls: Frozen Blueberries, Alfalfa Sprouts Sicken Dozens Across the US

Hiding in Plain Air: Recognizing Endemic Mycoses in Community-Acquired Pneumonia

Infectious Disease Regulatory Watch: August Highlights

This Week's Top 5 Infectious Disease News Stories: August 15-August 21, 2026
Shorts










Podcasts
Contagion Digital Edition









Continuing Medical Education
All News

Newly released CDC data show childhood immunization rates have steadily declined since 2020, pushing measles vaccination coverage below the threshold needed for herd immunity and leaving an estimated 280,000 kindergartners without documented vaccinations this year. Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the latest vaccine data, geographic patterns, and how public health and school officials can address this continued trend.

Fluoroquinolone prescribing emerged as key driver of AMR in multiple pathogens in a 14-year study period at US Veterans Affairs medical centers.

Cases and deaths continue to increase in the Democratic Republic of Congo, but the country's neighbor, Uganda, is declared Ebola-free.

With the news this week that childhood vaccine exemptions were at a historical high, it is important to understand what they are and how they are applied. Pediatrician Sharon Nachman, MD, offers some insights around the ability to forgo vaccines because of exemptions.

As of August 17, federal officials are reporting more than 15, 716 cases, hundreds of hospitalizations, and nearly all US states have been affected.

The latest national numbers shows a decrease in vaccination continues along with a spike in the number of immunization exemptions leading to an increase in the number of cases for vaccine-preventable diseases such as measles.

In the second episode with Jason M. Goldman, MD, MACP, he touches upon the legal side of the order and how it may affect the childhood vaccine schedule.

FDA has assigned its highest-risk Class I classification to a recall of nearly 19 million eggs linked to a multistate salmonella enteritidis outbreak that has sickened 98 people across 17 states.

Daptomycin-resistant Enterococcus faecium bacteremia is an emerging, high-mortality challenge in transplant and other high-risk patients, requiring early recognition, aggressive source control, and reliance on limited alternatives—most notably linezolid—with combination or salvage therapies considered when options are constrained.

This week's infectious disease news spans a broad-spectrum carbapenem review, an expanding jalapeño-linked salmonella recall, the EU approval of Maviret for acute hepatitis C, and clinician backlash against President Trump's executive order reshaping the childhood vaccine schedule.

In the second part of the interview with Sharon Nachman, MD, she touches upon how the administration’s shared clinical decision-making category related to childhood vaccines will affect the hepatitis B and rotavirus vaccines and the expectations there will be subsequent disease increases.

Jason M. Goldman, MD, MACP, discusses the potentially damaging effects of the rhetoric coming from the presidential executive order including downstream consequences as well as his concerns around the prospective findings of the HHS Task Force on Safer Childhood Vaccines associated with it.

The presidential executive order changing the measles, mumps and rubella (MMR) vaccine from a combination to a single-antigen vaccine means children will get more shots not less. Sharon Nachman, MD, offers some insights around the challenges of how the order’s latest changes could affect pediatric vaccine schedules.

The EU recently approved glecaprevir/pibrentasvir (Maviret), an eight-week direct-acting antiviral regimen, which offers people with hepatitis C the fastest treatment option available, giving European health systems a new tool in aiding the World Health Organization's goal of eliminating the virus by 2030.

The FDA has accepted EIT Pharma's new drug application for lonafarnib, an investigational oral therapy for chronic hepatitis D, supported by the phase 3 D-LIVR study, the largest clinical trial conducted to date in the disease.
















































































































































































